<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39106427</PMID><DateCompleted><Year>2024</Year><Month>08</Month><Day>06</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2332-7812</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>5</Issue><PubDate><Year>2024</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Neurology(R) neuroimmunology &amp; neuroinflammation</Title><ISOAbbreviation>Neurol Neuroimmunol Neuroinflamm</ISOAbbreviation></Journal><ArticleTitle>Clinical and Immunologic Effects of Paraprobiotics in Long-COVID Patients: A Pilot Study.</ArticleTitle><Pagination><StartPage>e200296</StartPage><MedlinePgn>e200296</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e200296</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1212/NXI.0000000000200296</ELocationID><Abstract><AbstractText Label="BACKGROUND AND OBJECTIVES" NlmCategory="OBJECTIVE">After the enormous health burden during the acute stages of the COVID-19 pandemic, we are now facing another important challenge, that is, long-COVID, a clinical condition with often disabling signs and symptoms of the neuropsychiatric, gastrointestinal, respiratory, cardiovascular, and immune systems. While the pathogenesis of this syndrome is still poorly understood, alterations of immune function and the gut microbiota seem to play important roles. Because affected individuals are frequently unable to work for prolonged periods and suffer numerous health compromises, effective treatments represent a major unmet medical need. Multiple potential therapies have been tried, but none is approved yet. Approaches that are able to influence the immune system and gut microbiota such as probiotics and paraprobiotics, i.e., nonviable probiotics, seem promising candidates. We, therefore, evaluated the clinical and immunologic effects of paraprobiotics in a small pilot study.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A total of 6 patients with long-COVID were followed systematically for more than 12 months after disease onset using standardized validated questionnaires, a smartphone app, and wearable sensors to assess neurocognitive function, fatigue, depressiveness, autonomic nervous system alterations, and quality of life. We then offered patients defined paraprobiotics for 4 weeks and evaluated them at the end of the treatment period using the same questionnaires, smartphone app, and wearable sensors. In addition, a comprehensive immunophenotyping and gut microbiota analysis was performed before and after treatment.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Improvements in several of the neurologic symptoms such as dysautonomia, fatigue, and depression were documented using both patient-reported outcomes and data from the smartphone app and wearable sensors. Of interest, the expression of activation markers on some immune cell populations such as B cells and nonclassical monocytes and the expression of toll-like receptor 2 (TLR2) on T cells were reduced after paraprobiotics treatment.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">Our results suggest that paraprobiotics might exert positive effects in patients with long-COVID most likely by modulating immune cell activation and expression of TLR2 on T cells. Further studies with paraprobiotics should confirm the promising observations of this small pilot study and hopefully not only improve the outcome of long-COVID but also unravel the pathomechanisms of this condition.</AbstractText><AbstractText Label="CLASSIFICATION OF EVIDENCE" NlmCategory="METHODS">This study provides Class IV evidence that paraprobiotics increase the probability of favorable changes of clinical and immunologic markers in patients with long-COVID.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Docampo</LastName><ForeName>Mar&#xed;a Jos&#xe9;</ForeName><Initials>MJ</Initials><Identifier Source="ORCID">0000-0003-1242-222X</Identifier><AffiliationInfo><Affiliation>From the Neuroimmunology and MS Research (nims) (M.J.D., M.B., P.O., E.B.-C., M.H., A.L., R.M., M.S.), Department of Neurology, University Hospital and University Zurich; Institute for Implementation Science in Health Care (P.O.), University of Z&#xfc;rich; Cellerys AG (P.O., A.L., R.M., M.S.), Schlieren; Universit&#xe4;ts-Kinderspital Z&#xfc;rich (E.B.-C.); Neurozentrum Bellevue (M.H., A.L.); PharmaBiome AG (G.L.), Schlieren, Switzerland; and Therapeutic Immune Design (R.M.), Center for Molecular Medicine, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Batruch</LastName><ForeName>Mattei</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>From the Neuroimmunology and MS Research (nims) (M.J.D., M.B., P.O., E.B.-C., M.H., A.L., R.M., M.S.), Department of Neurology, University Hospital and University Zurich; Institute for Implementation Science in Health Care (P.O.), University of Z&#xfc;rich; Cellerys AG (P.O., A.L., R.M., M.S.), Schlieren; Universit&#xe4;ts-Kinderspital Z&#xfc;rich (E.B.-C.); Neurozentrum Bellevue (M.H., A.L.); PharmaBiome AG (G.L.), Schlieren, Switzerland; and Therapeutic Immune Design (R.M.), Center for Molecular Medicine, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oldrati</LastName><ForeName>Pietro</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0001-5551-4306</Identifier><AffiliationInfo><Affiliation>From the Neuroimmunology and MS Research (nims) (M.J.D., M.B., P.O., E.B.-C., M.H., A.L., R.M., M.S.), Department of Neurology, University Hospital and University Zurich; Institute for Implementation Science in Health Care (P.O.), University of Z&#xfc;rich; Cellerys AG (P.O., A.L., R.M., M.S.), Schlieren; Universit&#xe4;ts-Kinderspital Z&#xfc;rich (E.B.-C.); Neurozentrum Bellevue (M.H., A.L.); PharmaBiome AG (G.L.), Schlieren, Switzerland; and Therapeutic Immune Design (R.M.), Center for Molecular Medicine, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berenjeno-Correa</LastName><ForeName>Ernesto</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>From the Neuroimmunology and MS Research (nims) (M.J.D., M.B., P.O., E.B.-C., M.H., A.L., R.M., M.S.), Department of Neurology, University Hospital and University Zurich; Institute for Implementation Science in Health Care (P.O.), University of Z&#xfc;rich; Cellerys AG (P.O., A.L., R.M., M.S.), Schlieren; Universit&#xe4;ts-Kinderspital Z&#xfc;rich (E.B.-C.); Neurozentrum Bellevue (M.H., A.L.); PharmaBiome AG (G.L.), Schlieren, Switzerland; and Therapeutic Immune Design (R.M.), Center for Molecular Medicine, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hilty</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>From the Neuroimmunology and MS Research (nims) (M.J.D., M.B., P.O., E.B.-C., M.H., A.L., R.M., M.S.), Department of Neurology, University Hospital and University Zurich; Institute for Implementation Science in Health Care (P.O.), University of Z&#xfc;rich; Cellerys AG (P.O., A.L., R.M., M.S.), Schlieren; Universit&#xe4;ts-Kinderspital Z&#xfc;rich (E.B.-C.); Neurozentrum Bellevue (M.H., A.L.); PharmaBiome AG (G.L.), Schlieren, Switzerland; and Therapeutic Immune Design (R.M.), Center for Molecular Medicine, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leventhal</LastName><ForeName>Gabriel</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>From the Neuroimmunology and MS Research (nims) (M.J.D., M.B., P.O., E.B.-C., M.H., A.L., R.M., M.S.), Department of Neurology, University Hospital and University Zurich; Institute for Implementation Science in Health Care (P.O.), University of Z&#xfc;rich; Cellerys AG (P.O., A.L., R.M., M.S.), Schlieren; Universit&#xe4;ts-Kinderspital Z&#xfc;rich (E.B.-C.); Neurozentrum Bellevue (M.H., A.L.); PharmaBiome AG (G.L.), Schlieren, Switzerland; and Therapeutic Immune Design (R.M.), Center for Molecular Medicine, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lutterotti</LastName><ForeName>Andreas</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>From the Neuroimmunology and MS Research (nims) (M.J.D., M.B., P.O., E.B.-C., M.H., A.L., R.M., M.S.), Department of Neurology, University Hospital and University Zurich; Institute for Implementation Science in Health Care (P.O.), University of Z&#xfc;rich; Cellerys AG (P.O., A.L., R.M., M.S.), Schlieren; Universit&#xe4;ts-Kinderspital Z&#xfc;rich (E.B.-C.); Neurozentrum Bellevue (M.H., A.L.); PharmaBiome AG (G.L.), Schlieren, Switzerland; and Therapeutic Immune Design (R.M.), Center for Molecular Medicine, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>Roland</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>From the Neuroimmunology and MS Research (nims) (M.J.D., M.B., P.O., E.B.-C., M.H., A.L., R.M., M.S.), Department of Neurology, University Hospital and University Zurich; Institute for Implementation Science in Health Care (P.O.), University of Z&#xfc;rich; Cellerys AG (P.O., A.L., R.M., M.S.), Schlieren; Universit&#xe4;ts-Kinderspital Z&#xfc;rich (E.B.-C.); Neurozentrum Bellevue (M.H., A.L.); PharmaBiome AG (G.L.), Schlieren, Switzerland; and Therapeutic Immune Design (R.M.), Center for Molecular Medicine, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sospedra</LastName><ForeName>Mireia</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>From the Neuroimmunology and MS Research (nims) (M.J.D., M.B., P.O., E.B.-C., M.H., A.L., R.M., M.S.), Department of Neurology, University Hospital and University Zurich; Institute for Implementation Science in Health Care (P.O.), University of Z&#xfc;rich; Cellerys AG (P.O., A.L., R.M., M.S.), Schlieren; Universit&#xe4;ts-Kinderspital Z&#xfc;rich (E.B.-C.); Neurozentrum Bellevue (M.H., A.L.); PharmaBiome AG (G.L.), Schlieren, Switzerland; and Therapeutic Immune Design (R.M.), Center for Molecular Medicine, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurol Neuroimmunol Neuroinflamm</MedlineTA><NlmUniqueID>101636388</NlmUniqueID><ISSNLinking>2332-7812</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019936" MajorTopicYN="Y">Probiotics</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="Y">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069196" MajorTopicYN="Y">Gastrointestinal Microbiome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors report no relevant disclosures. Go to Neurology.org/NN for full disclosures.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>8</Month><Day>6</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>8</Month><Day>6</Day><Hour>18</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>8</Month><Day>6</Day><Hour>16</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39106427</ArticleId><ArticleId IdType="pmc">PMC11318528</ArticleId><ArticleId IdType="doi">10.1212/NXI.0000000000200296</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Koc HC, Xiao J, Liu W, Li Y, Chen G. Long COVID and its management. Int J Biol Sci. 2022;18(12):4768-4780. doi:10.7150/ijbs.75056</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/ijbs.75056</ArticleId><ArticleId IdType="pmc">PMC9305273</ArticleId><ArticleId IdType="pubmed">35874958</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y, Yuan D, Chen DG, et al. . Multiple early factors anticipate post-acute COVID-19 sequelae. Cell. 2022;185(5):881-895.e20. doi:10.1016/j.cell.2022.01.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.01.014</ArticleId><ArticleId IdType="pmc">PMC8786632</ArticleId><ArticleId IdType="pubmed">35216672</ArticleId></ArticleIdList></Reference><Reference><Citation>Phetsouphanh C, Darley DR, Wilson DB, et al. . Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat Immunol. 2022;23(2):210-216. doi:10.1038/s41590-021-01113-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-01113-x</ArticleId><ArticleId IdType="pubmed">35027728</ArticleId></ArticleIdList></Reference><Reference><Citation>Greene C, Connolly R, Brennan D, et al. . Blood&#x2013;brain barrier disruption and sustained systemic inflammation in individuals with long COVID-associated cognitive impairment. Nat Neurosci. 2024;27(3):421-432. doi:10.1038/s41593-024-01576-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-024-01576-9</ArticleId><ArticleId IdType="pmc">PMC10917679</ArticleId><ArticleId IdType="pubmed">38388736</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong AC, Devason AS, Umana IC, et al. . Serotonin reduction in post-acute sequelae of viral infection. Cell. 2023;186(22):4851-4867.e20. doi:10.1016/j.cell.2023.09.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2023.09.013</ArticleId><ArticleId IdType="pmc">PMC11227373</ArticleId><ArticleId IdType="pubmed">37848036</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Q, Mak JWY, Su Q, et al. . Gut microbiota dynamics in a prospective cohort of patients with post-acute COVID-19 syndrome. Gut. 2022;71(3):544-552. doi:10.1136/gutjnl-2021-325989</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2021-325989</ArticleId><ArticleId IdType="pubmed">35082169</ArticleId></ArticleIdList></Reference><Reference><Citation>Cervia-Hasler C, Br&#xfc;ningk SC, Hoch T, et al. . Persistent complement dysregulation with signs of thromboinflammation in active Long Covid. Science. 2024;383(6680):eadg7942. doi:10.1126/science.adg7942</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.adg7942</ArticleId><ArticleId IdType="pubmed">38236961</ArticleId></ArticleIdList></Reference><Reference><Citation>Varesi A, Deumer U-S, Ananth S, Ricevuti G. The emerging role of gut microbiota in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): current evidence and potential therapeutic applications. J Clin Med. 2021;10(21):5077. doi:10.3390/jcm10215077</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm10215077</ArticleId><ArticleId IdType="pmc">PMC8584653</ArticleId><ArticleId IdType="pubmed">34768601</ArticleId></ArticleIdList></Reference><Reference><Citation>Corbitt M, Campagnolo N, Staines D, Marshall-Gradisnik S. A systematic review of probiotic interventions for gastrointestinal symptoms and irritable bowel syndrome in chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME). Probiotics Antimicrob Proteins. 2018;10(3):466-477. doi:10.1007/s12602-018-9397-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12602-018-9397-8</ArticleId><ArticleId IdType="pubmed">29464501</ArticleId></ArticleIdList></Reference><Reference><Citation>Alenazy MF, Aljohar HI, Alruwaili AR, et al. . Gut microbiota dynamics in relation to long-COVID-19 syndrome: role of probiotics to combat psychiatric complications. Metabolites. 2022;12(10):912. doi:10.3390/metabo12100912</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/metabo12100912</ArticleId><ArticleId IdType="pmc">PMC9611210</ArticleId><ArticleId IdType="pubmed">36295814</ArticleId></ArticleIdList></Reference><Reference><Citation>Siciliano RA, Reale A, Mazzeo MF, Morandi S, Silvetti T, Brasca M. Paraprobiotics: a new perspective for functional foods and nutraceuticals. Nutrients. 2021;13(4):1225. doi:10.3390/nu13041225</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu13041225</ArticleId><ArticleId IdType="pmc">PMC8068161</ArticleId><ArticleId IdType="pubmed">33917707</ArticleId></ArticleIdList></Reference><Reference><Citation>Akter S, Park J-H, Jung HK. Potential health-promoting benefits of paraprobiotics, inactivated probiotic cells. J Microbiol Biotechnol. 2020;30(4):477-481. doi:10.4014/jmb.1911.11019</Citation><ArticleIdList><ArticleId IdType="doi">10.4014/jmb.1911.11019</ArticleId><ArticleId IdType="pmc">PMC9728361</ArticleId><ArticleId IdType="pubmed">31986247</ArticleId></ArticleIdList></Reference><Reference><Citation>De Almada CN, Almada CN, Martinez RCR, Sant'Ana AS. Paraprobiotics: evidences on their ability to modify biological responses, inactivation methods and perspectives on their application in foods. Trends Food Sci Technol. 2016;58:96-114. doi:10.1016/j.tifs.2016.09.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tifs.2016.09.011</ArticleId></ArticleIdList></Reference><Reference><Citation>Taverniti V, Guglielmetti S. The immunomodulatory properties of probiotic microorganisms beyond their viability (ghost probiotics: proposal of paraprobiotic concept). Genes Nutr. 2011;6(3):261-274. doi:10.1007/s12263-011-0218-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12263-011-0218-x</ArticleId><ArticleId IdType="pmc">PMC3145061</ArticleId><ArticleId IdType="pubmed">21499799</ArticleId></ArticleIdList></Reference><Reference><Citation>Sletten DM, Suarez GA, Low PA, Mandrekar J, Singer W. Compass 31: a refined and abbreviated composite autonomic symptom score. Mayo Clin Proc. 2012;87(12):1196-1201. doi:10.1016/j.mayocp.2012.10.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mayocp.2012.10.013</ArticleId><ArticleId IdType="pmc">PMC3541923</ArticleId><ArticleId IdType="pubmed">23218087</ArticleId></ArticleIdList></Reference><Reference><Citation>Cortez MM, Nagi Reddy SK, Goodman B, Carter JL, Wingerchuk DM. Autonomic symptom burden is associated with MS-related fatigue and quality of life. Mult Scler Relat Disord. 2015;4(3):258-263. doi:10.1016/j.msard.2015.03.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.msard.2015.03.007</ArticleId><ArticleId IdType="pubmed">26008943</ArticleId></ArticleIdList></Reference><Reference><Citation>Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473-483. doi:10.1097/00005650-199206000-00002</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005650-199206000-00002</ArticleId><ArticleId IdType="pubmed">1593914</ArticleId></ArticleIdList></Reference><Reference><Citation>orthotoolkit.com/oswestry/</Citation></Reference><Reference><Citation>Roser K, Mader L, Baenziger J, Sommer G, Kuehni CE, Michel G. Health-related quality of life in Switzerland: normative data for the SF-36v2 questionnaire. Qual Life Res. 2019;28(7):1963-1977. doi:10.1007/s11136-019-02161-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11136-019-02161-5</ArticleId><ArticleId IdType="pmc">PMC6571102</ArticleId><ArticleId IdType="pubmed">30848444</ArticleId></ArticleIdList></Reference><Reference><Citation>Laucis NC, Hays RD, Bhattacharyya T. Scoring the SF-36 in orthopaedics: a brief guide. J Bone Joint Surg Am. 2015;97(19):1628-1634. doi:10.2106/JBJS.O.00030</Citation><ArticleIdList><ArticleId IdType="doi">10.2106/JBJS.O.00030</ArticleId><ArticleId IdType="pmc">PMC5029523</ArticleId><ArticleId IdType="pubmed">26446970</ArticleId></ArticleIdList></Reference><Reference><Citation>Kroenke K, Spitzer RL, Williams JBW. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606-613. doi:10.1046/j.1525-1497.2001.016009606.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1525-1497.2001.016009606.x</ArticleId><ArticleId IdType="pmc">PMC1495268</ArticleId><ArticleId IdType="pubmed">11556941</ArticleId></ArticleIdList></Reference><Reference><Citation>Levis B, Benedetti A, Thombs BD, DEPRESsion Screening Data DEPRESSD Collaboration. Accuracy of patient health questionnaire-9 (PHQ-9) for screening to detect major depression: individual participant data meta-analysis. BMJ. 2019;365:l1476. doi:10.1136/bmj.l1476</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.l1476</ArticleId><ArticleId IdType="pmc">PMC6454318</ArticleId><ArticleId IdType="pubmed">30967483</ArticleId></ArticleIdList></Reference><Reference><Citation>Kedor C, Freitag H, Meyer-Arndt L, et al. . A prospective observational study of post-COVID-19 chronic fatigue syndrome following the first pandemic wave in Germany and biomarkers associated with symptom severity. Nat Commun. 2022;13(1):5104. doi:10.1038/s41467-022-32507-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-32507-6</ArticleId><ArticleId IdType="pmc">PMC9426365</ArticleId><ArticleId IdType="pubmed">36042189</ArticleId></ArticleIdList></Reference><Reference><Citation>Gashi S, Oldrati P, Moebus M, et al. . Modeling multiple sclerosis using mobile and wearable sensor data. NPJ Digit Med. 2024;7(1):64. doi:10.1038/s41746-024-01025-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41746-024-01025-8</ArticleId><ArticleId IdType="pmc">PMC10928076</ArticleId><ArticleId IdType="pubmed">38467710</ArticleId></ArticleIdList></Reference><Reference><Citation>Arbeitsgruppe Diagnostik der Deutschen Gesellschaft f&#xfc;r Schlafforschung und Schlafmedizin DGSM, Hoffmann RM, M&#xfc;ller T, Hajak G, Cassel W. Abend-Morgenprotokolle in Schlafforschung und Schlafmedizin&#x2014;Ein Standardinstrument f&#xfc;r den deutschsprachigen Raum. Somnologie. 1997;1(3):103-109. doi:10.1007/s11818-997-0019-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11818-997-0019-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrios L, Oldrati P, Hilty M, et al. . Smartphone-based tapping frequency as a surrogate for perceived fatigue: an in-the-wild feasibility study in multiple sclerosis patients. Proc ACM Interact Mob Wearable Ubiquitous Technol 2021;5:1-30.</Citation></Reference><Reference><Citation>Naegele M, Tillack K, Reinhardt S, Schippling S, Martin R, Sospedra M. Neutrophils in multiple sclerosis are characterized by a primed phenotype. J Neuroimmunol. 2012;242(1-2):60-71. doi:10.1016/j.jneuroim.2011.11.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2011.11.009</ArticleId><ArticleId IdType="pubmed">22169406</ArticleId></ArticleIdList></Reference><Reference><Citation>Tillack K, Breiden P, Martin R, Sospedra MT. T lymphocyte priming by neutrophil extracellular traps links innate and adaptive immune responses. J Immunol. 2012;188(7):3150-3159. doi:10.4049/jimmunol.1103414</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1103414</ArticleId><ArticleId IdType="pubmed">22351936</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao P, Liu J, Liu M. Effect of COVID-19 vaccines on reducing the risk of long COVID in the real world: a systematic review and meta-analysis. Int J Environ Res Public Health. 2022;19(19):12422. doi:10.3390/ijerph191912422</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph191912422</ArticleId><ArticleId IdType="pmc">PMC9566528</ArticleId><ArticleId IdType="pubmed">36231717</ArticleId></ArticleIdList></Reference><Reference><Citation>Hampshire A, Azor A, Atchison C, et al. . Cognition and memory after Covid-19 in a large community sample. N Engl J Med. 2024;390(9):806-818. doi:10.1056/NEJMoa2311330</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2311330</ArticleId><ArticleId IdType="pmc">PMC7615803</ArticleId><ArticleId IdType="pubmed">38416429</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21(3):133-146. doi:10.1038/s41579-022-00846-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00846-2</ArticleId><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Monje M, Iwasaki A. The neurobiology of long COVID. Neuron. 2022;110(21):3484-3496. doi:10.1016/j.neuron.2022.10.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2022.10.006</ArticleId><ArticleId IdType="pmc">PMC9537254</ArticleId><ArticleId IdType="pubmed">36288726</ArticleId></ArticleIdList></Reference><Reference><Citation>Stewart JM. Autonomic nervous system dysfunction in adolescents with postural orthostatic tachycardia syndrome and chronic fatigue syndrome is characterized by attenuated vagal baroreflex and potentiated sympathetic vasomotion. Pediatr Res. 2000;48(2):218-26. doi:10.1203/00006450-200008000-00016</Citation><ArticleIdList><ArticleId IdType="doi">10.1203/00006450-200008000-00016</ArticleId><ArticleId IdType="pubmed">10926298</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellocchi C, Carandina A, Montinaro B, et al. . The interplay between autonomic nervous system and inflammation across systemic autoimmune diseases. Int J Mol Sci. 2022;23(5):2449. doi:10.3390/ijms23052449</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23052449</ArticleId><ArticleId IdType="pmc">PMC8910153</ArticleId><ArticleId IdType="pubmed">35269591</ArticleId></ArticleIdList></Reference><Reference><Citation>Woodruff MC, Bonham KS, Anam FA, et al. . Chronic inflammation, neutrophil activity, and autoreactivity splits long COVID. Nat Commun. 2023;14(1):4201. doi:10.1038/s41467-023-40012-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-40012-7</ArticleId><ArticleId IdType="pmc">PMC10349085</ArticleId><ArticleId IdType="pubmed">37452024</ArticleId></ArticleIdList></Reference><Reference><Citation>Wechsler JB, Butuci M, Wong A, Kamboj AP, Youngblood BA. Mast cell activation is associated with post&#x2010;acute COVID&#x2010;19 syndrome. Allergy. 2022;77(4):1288-1291. doi:10.1111/all.15188</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/all.15188</ArticleId><ArticleId IdType="pmc">PMC9299596</ArticleId><ArticleId IdType="pubmed">34820848</ArticleId></ArticleIdList></Reference><Reference><Citation>Rastogi I, Jeon D, Moseman JE, Muralidhar A, Potluri HK, McNeel DG. Role of B cells as antigen presenting cells. Front Immunol. 2022;13:954936. doi:10.3389/fimmu.2022.954936</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.954936</ArticleId><ArticleId IdType="pmc">PMC9493130</ArticleId><ArticleId IdType="pubmed">36159874</ArticleId></ArticleIdList></Reference><Reference><Citation>Suttles J, Milhorn DM, Miller RW, Poe JC, Wahl LM, Stout RD. CD40 signaling of monocyte inflammatory cytokine synthesis through an ERK1/2-dependent pathway. A target of interleukin (il)-4 and il-10 anti-inflammatory action. J Biol Chem. 1999;274(9):5835-5842. doi:10.1074/jbc.274.9.5835</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.274.9.5835</ArticleId><ArticleId IdType="pubmed">10026206</ArticleId></ArticleIdList></Reference><Reference><Citation>Narasimhan PB, Marcovecchio P, Hamers AAJ, Hedrick CC. Nonclassical monocytes in health and disease. Annu Rev Immunol. 2019;37:439-456. doi:10.1146/annurev-immunol-042617-053119</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-immunol-042617-053119</ArticleId><ArticleId IdType="pubmed">31026415</ArticleId></ArticleIdList></Reference><Reference><Citation>Komai-Koma M, Jones L, Ogg GS, Xu D, Liew FY. TLR2 is expressed on activated T cells as a costimulatory receptor. Proc Natl Acad Sci U S A. 2004;101(9):3029-3034. doi:10.1073/pnas.0400171101</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0400171101</ArticleId><ArticleId IdType="pmc">PMC365739</ArticleId><ArticleId IdType="pubmed">14981245</ArticleId></ArticleIdList></Reference><Reference><Citation>Cottalorda A, Verschelde C, Mar&#xe7;ais A, et al. . TLR2 engagement on CD8 T cells lowers the thresholdfor optimal antigen-induced T cell activation. Eur J Immunol. 2006;36(7):1684-1693. doi:10.1002/eji.200636181</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.200636181</ArticleId><ArticleId IdType="pubmed">16761317</ArticleId></ArticleIdList></Reference><Reference><Citation>Mercier BC, Cottalorda A, Coupet C-A, Marvel J, Bonnefoy-B&#xe9;rard N. TLR2 engagement on CD8 T cells Enables Generation of functional memory cells in response to a Suboptimal TCR signal. J Immunol. 2009;182(4):1860-1867. doi:10.4049/jimmunol.0801167</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.0801167</ArticleId><ArticleId IdType="pubmed">19201838</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng M, Karki R, Williams EP, et al. . TLR2 senses the SARS-CoV-2 envelope protein to produce inflammatory cytokines. Nat Immunol. 2021;22(7):829-838. doi:10.1038/s41590-021-00937-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-00937-x</ArticleId><ArticleId IdType="pmc">PMC8882317</ArticleId><ArticleId IdType="pubmed">33963333</ArticleId></ArticleIdList></Reference><Reference><Citation>Aboudounya MM, Heads RJ. COVID-19 and toll-like receptor 4 (TLR4): SARS-CoV-2 may bind and activate TLR4 to increase ACE2 expression, facilitating entry and causing hyperinflammation. Mediators Inflamm. 2021;2021:8874339. doi:10.1155/2021/8874339</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2021/8874339</ArticleId><ArticleId IdType="pmc">PMC7811571</ArticleId><ArticleId IdType="pubmed">33505220</ArticleId></ArticleIdList></Reference><Reference><Citation>Bezemer GFG, Garssen J. TLR9 and COVID-19: a multidisciplinary theory of a multifaceted therapeutic target. Front Pharmacol. 2020;11:601685. doi:10.3389/fphar.2020.601685</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2020.601685</ArticleId><ArticleId IdType="pmc">PMC7844586</ArticleId><ArticleId IdType="pubmed">33519463</ArticleId></ArticleIdList></Reference><Reference><Citation>Szabo MP, Iba M, Nath A, Masliah E, Kim C. Does SARS-CoV-2 affect neurodegenerative disorders? TLR2, a potential receptor for SARS-CoV-2 in the CNS. Exp Mol Med. 2022;54(4):447-454. doi:10.1038/s12276-022-00755-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s12276-022-00755-7</ArticleId><ArticleId IdType="pmc">PMC8990637</ArticleId><ArticleId IdType="pubmed">35396576</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>